logo
ProjectUnder Construction

Vacaville Biopharmaceutical Manufacturing Site

One of 10,000+ projects Taiyo tracks in California.

Source: Site Selection Magazine

Lonza AG is acquiring the former Genentech plant in Vacaville, California, and plans to invest $551.4 million to transform it into one of the largest drug manufacturing operations globally. This investment aims to enhance the facility's capacity for biopharmaceutical production and create a significant presence in the West Coast biotech sector.

Status
Under Construction
Sector
Manufacturing (Industrial)
Location
Vacaville, California, United States of America
Updated
22 Jul 2026
Source
Site Selection Magazine

ConstructChat

Ask ConstructChat about Vacaville Biopharmaceutical Manufacturing Site

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Vacaville Biopharmaceutical Manufacturing Site” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Vacaville, California, United States. Taiyo aggregates data on it from Site Selection Magazine.

Participants

Not available for this record.

Status

Original status

under construction

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Lonza AG is acquiring the former Genentech plant in Vacaville, California, and plans to invest $551.4 million to transform it into one of the largest drug manufacturing operations globally. This investment aims to enhance the facility's capacity for biopharmaceutical production and create a significant presence in the West Coast biotech sector.

Original sector

Biotechnology

Budget

Location

Country

United States of America (USA)

State

California

City

Vacaville

Source

Source

Site Selection Magazine

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial)

Article published date

2025-03-25

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project